In contrast, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, which control hyperglycaemia by inducing increased glycosuric effects, were shown to have a neutral or slightly positive effect on bone turnover and BMD in the long term [36]. This evidence concerns the gene SLC5A2 and Hyperglycemia.